Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009–2018.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Publication Year:
      2019
    • Abstract:
      Background and Objective: Integrase strand transfer inhibitors (INSTIs) have become the preferred first-line antiretroviral therapy in adults. There is paucity of published data on their use in children outside of clinical trials, particularly long-term safety and tolerability. This study aimed to describe INSTI use including the number of, and reasons for INSTI discontinuation. Methods: We conducted a retrospective cohort analysis by database and electronic record review of children aged under 18 years with perinatally acquired human immunodeficiency virus who started INSTI-based antiretroviral therapy between May 2009 and March 2018, in a single tertiary centre. Results: Fifty-six INSTI-based regimens were prescribed in 54 children, 64.9% from 2015 onwards. Twenty-one of 56 (37.5%) regimens commenced with raltegravir, 29 (51.8%) with dolutegravir and six (10.7%) with elvitegravir. The median age at the start of treatment was 15 years (interquartile range 13.5–16.4) with a median duration of INSTI-antiretroviral therapy of 1.65 years (range 0.01–8.8). Twenty-four children had a detectable viral load at the start INSTI therapy; 20 (83%) achieving viral suppression in a median of 26 days (interquartile range 19.5–34.5). There were 26 discontinuations of INSTI-based antiretroviral therapy after a median of 183 days; 9/26 because of adverse events. Four of nine adverse events were attributed to INSTI use, all in patients taking dolutegravir and the adverse events were neuropsychiatric and gastrointestinal in nature. Conclusions: INSTI-based regimens were generally efficacious and well tolerated in this paediatric cohort, with 4/26 discontinuations due to INSTI-attributed adverse events. Further post-marketing surveillance of INSTI use in children is warranted. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Clinical Drug Investigation is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • ISSN:
      11732563
    • Accession Number:
      136861704
  • Citations
    • ABNT:
      ABO, Y.-N. et al. Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009–2018. Clinical Drug Investigation, [s. l.], v. 39, n. 6, p. 585, 2019. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=136861704. Acesso em: 25 out. 2020.
    • AMA:
      Abo Y-N, Refsum E, Mackie N, Lyall H, Tudor-Williams G, Foster C. Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009–2018. Clinical Drug Investigation. 2019;39(6):585. Accessed October 25, 2020. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=136861704
    • APA:
      Abo, Y.-N., Refsum, E., Mackie, N., Lyall, H., Tudor-Williams, G., & Foster, C. (2019). Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009–2018. Clinical Drug Investigation, 39(6), 585.
    • Chicago/Turabian: Author-Date:
      Abo, Yara-Natalie, Erika Refsum, Nicola Mackie, Hermione Lyall, Gareth Tudor-Williams, and Caroline Foster. 2019. “Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009–2018.” Clinical Drug Investigation 39 (6): 585. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=136861704.
    • Harvard:
      Abo, Y.-N. et al. (2019) ‘Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009–2018’, Clinical Drug Investigation, 39(6), p. 585. Available at: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=136861704 (Accessed: 25 October 2020).
    • Harvard: Australian:
      Abo, Y-N, Refsum, E, Mackie, N, Lyall, H, Tudor-Williams, G & Foster, C 2019, ‘Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009–2018’, Clinical Drug Investigation, vol. 39, no. 6, p. 585, viewed 25 October 2020, .
    • MLA:
      Abo, Yara-Natalie, et al. “Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009–2018.” Clinical Drug Investigation, vol. 39, no. 6, June 2019, p. 585. EBSCOhost, search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=136861704.
    • Chicago/Turabian: Humanities:
      Abo, Yara-Natalie, Erika Refsum, Nicola Mackie, Hermione Lyall, Gareth Tudor-Williams, and Caroline Foster. “Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009–2018.” Clinical Drug Investigation 39, no. 6 (June 2019): 585. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=136861704.
    • Vancouver/ICMJE:
      Abo Y-N, Refsum E, Mackie N, Lyall H, Tudor-Williams G, Foster C. Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009–2018. Clinical Drug Investigation [Internet]. 2019 Jun [cited 2020 Oct 25];39(6):585. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=136861704